MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer

By sjmartinez • October 11, 2023

Crowell PD, Giafaglione JM, Jones AE, Nunley NM, Hashimoto T, Delcourt AML, Petcherski A, Agrawal R, Bernard MJ, Diaz JA, Heering KY, Huang RR, Low JY, Matulionis N, Navone NM, Ye H, Zoubeidi A, Christofk HR, Rettig MB, Reiter RE, Haffner MC, Boutros PC, Shirihai OS, Divakaruni AS, Goldstein AS. MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer. Cell Rep. 2023 Oct 9;42(10):113221. doi: 10.1016/j.celrep.2023.113221. Epub ahead of print. PMID: 37815914.

Tags: Cancer, CP, Endocrinology, Metabolism, Publications

Related Posts

Oxidative stress-regulatory role of miR-10b-5p in the diabetic human cornea revealed through integrated multi-omics analysis

Zha D, Gamez J, Ebrahimi SM, Wang Y, Verma N, Poe AJ, White S, Shah R, Kramerov AA, Sawant OB, Santiskulvong C, Stotland AB, Wang[...]

The gut microbiome promotes mitochondrial respiration in the brain of a Parkinson’s disease mouse model

Morais LH, Stiles L, Freeman M, Oguienko AD, Hoang JD, Ji J, Jones J, Quan B, Devine J, Bois JS, Chou TF, Trinh J, Picard[...]

Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors

Zhu L, Cheung YM, Chiang C, Gallagher EJ, Hamnvik OR, Mammen J, Quandt Z, Jones R, McDunn J, Al-Bahadili H, Angell T, Bancos I, Betof[...]